检测DNA损伤和TP53的功能作为调节器的敏感性,以卡利希胺基抗体-药物结合剂为急性白血病
Camryn M Pettenger-Willey1, George S Laszlo1, Margery Gang2
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Cancers
|January 10, 2026
概括
在急性白血病中对抗体药物合物如gemtuzumab ozogamicin (GO) 和 inotuzumab ozogamicin (InO) 的耐药性与TP53状态有关. 使用小分子抑制剂向DNA损伤途径可能会增强GO/InO的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 吉姆图祖马布臭胺 (GO) 和伊诺图祖马布臭胺 (InO) 是用于治疗急性白血病的抗体药物联合体 (ADC).
- 这些ADC向癌细胞输送有毒的卡利希胺素 (CLM) 衍生物.
- 对GO和INO抗性的机制尚未完全理解.
研究的目的:
- 为了确定赋予对卡利希胺素 (CLM) 敏感性或耐药性的基因.
- 研究TP53和其他DNA损伤反应基因在CLM耐药性中的作用.
- 探索组合疗法,以克服急性白血病中的CLM耐药性.
主要方法:
- 一个全基因组的CRISPR/Cas9屏幕被用来识别CLM敏感性基因.
- 在急性白血病细胞系上进行了确认性细胞毒性测试.
- 同源细胞系对与野生型 (WT) 和淘汰 (KO) TP53生成.
主要成果:
- TP53突变状态显著影响了CLM敏感性,TP53突变细胞的敏感性降低了10至1000倍.
- 与TP53 WT细胞相比,TP53淘汰细胞对CLM的敏感性显著降低.
- ATM和MDM2被确定为CLM细胞毒性的关键调节剂,在某些情况下独立于TP53状态.
- 伊达萨努特林 (MDM2抑制剂) 在TP53 WT细胞中增强了CLM细胞毒性,但在TP53突变细胞中没有.
- ATM 抑制剂 (AZD1390,lartesertib) 提高了CLM的疗效,无论TP53状态如何.
结论:
- TP53,ATM和MDM2是急性白血病中CLM诱导的细胞毒性的关键调节剂.
- 涉及基于CLM的ADC和向DNA损伤途径的小分子抑制剂的组合策略需要进一步调查.
- 这些发现支持开发新的治疗策略,以提高基于CLM的ADC在急性白血病治疗中的疗效.
关键词:
在CD2222中,我们可以看到CD22.CD3333 CD3333 CD3333 CD3333 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33这就是CRISPR/Cas9的作用.患有急性白血病的人.卡利希亚米辛是什么意思药物检查屏幕的使用情况.吉姆图祖马布 (gemtuzumab) 是一种奥佐加米的药物.伊诺图祖马布 (inotuzumab) 是一种奥佐加米辛的药物.更多相关视频
相关概念视频
DNA Damage can Stall the Cell Cycle
10.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.0K
DNA Damage Can Stall the Cell Cycle
3.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


